Edesa Biotech Inc $ 5.53 -0.26 (-4.49%)
Volume:
228,766
Avg Vol (1m):
179,030
Market Cap $:
58.19 Mil
Enterprise Value $:
51.14 Mil
P/E (TTM):
0.00
P/B:
7.77
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 43.99 | ||
| Equity-to-Asset | 0.62 | ||
| Debt-to-Equity | 0.03 | ||
| Debt-to-EBITDA | -0.03 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 5.95 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -1939.39 | ||
| Net Margin % | -1928.48 | ||
| ROE % | -112.07 | ||
| ROA % | -83.46 | ||
| ROC (Joel Greenblatt) % | -3013.18 | ||
| 3-Year Revenue Growth Rate | -65.6 | ||
| 3-Year EBITDA Growth Rate | 67.1 | ||
| 3-Year EPS without NRI Growth Rate | 67 |
EDSA
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 7.77 | ||
| PS Ratio | 141.8 | ||
| EV-to-EBIT | -8 | ||
| EV-to-EBITDA | -8.05 | ||
| EV-to-Revenue | 154.98 | ||
| Current Ratio | 5.3 | ||
| Quick Ratio | 5.3 | ||
| Days Inventory | 1674.71 | ||
| Days Sales Outstanding | 96.23 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -225.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 12.57 | ||
| Price-to-Median-PS-Value | 4.25 | ||
| Earnings Yield (Greenblatt) % | -12.51 |